John Newman
Stock Analyst at Canaccord Genuity
(2.18)
# 2,934
Out of 5,008 analysts
81
Total ratings
45.71%
Success rate
-4.56%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRUS Merus | Downgrades: Hold | $67 → $97 | $94.39 | +2.77% | 3 | Sep 30, 2025 | |
| MCRB Seres Therapeutics | Maintains: Buy | $14 → $22 | $20.09 | +9.51% | 10 | Sep 24, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $850 | $583.24 | +45.74% | 17 | Jul 23, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $1.35 | +937.04% | 3 | Mar 14, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $106.06 | +61.64% | 8 | Mar 11, 2025 | |
| ATRA Atara Biotherapeutics | Maintains: Buy | $17 | $15.63 | +8.77% | 5 | Mar 11, 2025 | |
| MRKR Marker Therapeutics | Initiates: Buy | $8 | $1.06 | +654.72% | 1 | Mar 5, 2025 | |
| CADL Candel Therapeutics | Maintains: Buy | $20 → $25 | $5.63 | +344.05% | 2 | Feb 26, 2025 | |
| DCTH Delcath Systems | Maintains: Buy | $21 | $10.80 | +94.44% | 1 | Oct 18, 2024 | |
| ACLX Arcellx | Maintains: Buy | $85 → $115 | $85.21 | +34.96% | 8 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $8 | $0.85 | +837.76% | 6 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $9.74 | +341.48% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.35 | +270.37% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $40.87 | +7.66% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $15.98 | +137.80% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $5.61 | +381.28% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $11.71 | - | 1 | Sep 13, 2017 |
Merus
Sep 30, 2025
Downgrades: Hold
Price Target: $67 → $97
Current: $94.39
Upside: +2.77%
Seres Therapeutics
Sep 24, 2025
Maintains: Buy
Price Target: $14 → $22
Current: $20.09
Upside: +9.51%
Regeneron Pharmaceuticals
Jul 23, 2025
Maintains: Buy
Price Target: $850
Current: $583.24
Upside: +45.74%
Allogene Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $14
Current: $1.35
Upside: +937.04%
BioNTech SE
Mar 11, 2025
Maintains: Buy
Price Target: $171
Current: $106.06
Upside: +61.64%
Atara Biotherapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $17
Current: $15.63
Upside: +8.77%
Marker Therapeutics
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.06
Upside: +654.72%
Candel Therapeutics
Feb 26, 2025
Maintains: Buy
Price Target: $20 → $25
Current: $5.63
Upside: +344.05%
Delcath Systems
Oct 18, 2024
Maintains: Buy
Price Target: $21
Current: $10.80
Upside: +94.44%
Arcellx
Oct 17, 2024
Maintains: Buy
Price Target: $85 → $115
Current: $85.21
Upside: +34.96%
Sep 11, 2024
Maintains: Buy
Price Target: $19 → $8
Current: $0.85
Upside: +837.76%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $9.74
Upside: +341.48%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $1.35
Upside: +270.37%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $40.87
Upside: +7.66%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $15.98
Upside: +137.80%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $5.61
Upside: +381.28%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $11.71
Upside: -